Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Incorporating biomarkers into clinical trial designs: points to consider

Nature Biotechnology volume 30, pages 596–599 (2012)Cite this article

Subjects

In an environment where the regulatory and reimbursement authorities continue to raise the bar for new oncology therapies, how are sponsors adapting clinical trial designs?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Regulatory Innovation. BioCentury 39, A1–A28, September 13, 2010.

  2. Jallal, B. Euro. Pharm. Rev. 16, 29–31 (2011).

    Google Scholar 

  3. LaVallee, T. Onc. News. 6, 52 (2011).

    Google Scholar 

  4. Heinemann, V. et al. Cancer Treat. Rev. 35, 262–271 (2009).

    Article  CAS  Google Scholar 

  5. Beckman, R.A. et al. Nat. Rev. Drug Discov. 10, 735–748 (2011).

    Article  CAS  Google Scholar 

  6. Sikorski, R. & Yao, B. Sci. Transl. Med. 1, 10ps11 (2009).

    Article  Google Scholar 

  7. Barker, A.D. et al. Clin. Pharmacol. Ther. 86, 97–100 (2009).

    Article  CAS  Google Scholar 

  8. Fleming, T. & Richardson, B.A. J. Infect. Dis. 190, 666–674 (2004).

    Article  CAS  Google Scholar 

  9. Patlak, M., Nass, S.J. & Balogh, E. The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care. http://books.nap.edu/openbook.php?record_id=13101 (The National Academies Press, Washington, DC, 2011).

    Book  Google Scholar 

  10. D'Agostino, R.B. N. Engl. J. Med., 365, e2 (2011).

    Article  CAS  Google Scholar 

  11. Chen, K. & Shan, M. Contemp. Clin. Trials 29, 32–41 (2008).

    Article  Google Scholar 

  12. Vickers, A.J., Ballen, V. & Scher, H.I. Clin. Cancer Res. 13, 972–976 (2007).

    Article  Google Scholar 

  13. Thall, P.F. UT MD Anderson Cancer Center Department of Biostatistics Working Paper Series http://biostats.bepress.com/mdandersonbiostat/paper35/ (2007).

    Google Scholar 

  14. Robert, C. et al. N. Engl. J. Med. 364, 2517–2526 (2011).

    Article  CAS  Google Scholar 

  15. Maitland, M. et al. J. Clin. Oncol. 29, 3109–3111 (2011).

    Article  Google Scholar 

  16. Hoos, A. et al. J. Natl. Cancer Inst. 102, 1388–1397 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Edward Bradley is therapeutic head and vice president, Clinical Development, Oncology, MedImmune, Gaithersburg, Maryland, USA.,

    Edward Bradley

Authors
  1. Edward Bradley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Bradley.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bradley, E. Incorporating biomarkers into clinical trial designs: points to consider. Nat Biotechnol 30, 596–599 (2012). https://doi.org/10.1038/nbt.2296

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2296

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research